Galecto Biotech AB has discovered β-D-galactopyranose compounds acting as galectin-1 (LGALS1) and/or galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.